Calpeptin treatment decreases cell density and proliferation. by Daniela M. Santos (211055)

Nicotine-induced Tumor Growth is decreased by BEL. by Lindsay E. Calderon (332344)

Sphere-forming efficiency decreases following radiation. by Vicky T. Nguyen (5029244)

Azurin decreases P-cadherin protein levels. by Nuno Bernardes (435240)

Prenatal stress decreases adult hippocampal neurogenesis. by Laure Belnoue (452010)

Cigarette smoke decreases clathrin mediated endocytosis. by Parker F. Duffney (8878145)

Tau aggregation decreased in mixed isoform reactions. by Stephanie J. Adams (364585)

Supplementary Material for: Cardiac Troponin Is Elevated in Patients with Thyrotoxicosis and Decreases as Thyroid Function Improves and Brain Natriuretic Peptide Levels Decrease by Watanabe N. (4118812)

“…Of the 27 patients with elevated hsTnI (≥5.0 pg/mL), the hsTnI level was normalized in 20 patients within a year. …”

miR-100 decreases tumor size. by Bahauddeen M. Alrfaei (484859)

Diabetic kidney shows decreased klotho expression. by Jeong Suk Kang (7359572)

“…<p>(a) Representative images of the kidney from normal and diabetic biopsies showing the decreased klotho expression in diabetic podocytes by IHC. …”

HFD decreases nephrocyte uptake of dextran and albumin. by Aleksandra Lubojemska (10746241)

Cellular co-infection decreases the potential for superinfection. by Brigitte E. Martin (8366847)

A picture of service-bed compartment of the gamma spectrometry vehicle used in the experiment. by Antanas Bukartas (10023785)

Fig 2 - by Megan Armstrong (1782073)

CONSORT diagram for prospective survey recruitment. by Megan Armstrong (1782073)

Patient characteristics by medical conditions pre-and post-prescription law. by Megan Armstrong (1782073)

Opioid medication use and patient satisfaction after hospital discharge. by Megan Armstrong (1782073)

Number of days and MMEs/kg prescribed at discharge by days to law change. by Megan Armstrong (1782073)

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”